Urogen Pharma (NASDAQ:URGN) executives used the company’s fiscal 2025 earnings call to highlight early commercial momentum for newly launched Zusduri, continued growth from its established product ...

EORTC Recurrence Score Analysis from the Pivotal ENVISION Trial to be Presented at the 2026 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO-GU 2026) PRINCETON, N.J., Feb.

BeOne Medicines Q4 earnings and revenue beat the Street's expectations; the outlook missed by a small margin. Read why I have ...

Further analysis using a Cox proportional hazards model showed that PrimeC treatment was associated with a 65% reduction in the risk of death compared to placebo (hazard ratio: 0.35; 95% CI: 0.17–0.71 ...

Outpatient data show 13.90% radiographic hip involvement in axial spondyloarthritis, linked to longer duration and higher disease severity.

Patients with resected Merkel cell carcinoma residing in Medicaid expansion states had greater survival rates than those in nonexpansion states.

Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse eventsCompany expects to complete enrollment of ...

Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2025 Earnings Call Transcript February 20, 2026 Operator: Ladies and gentlemen, thank you for standing by. My name is Colby, and I will be your conference ...

Objectives Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic autoimmune disease where infections ...

Background A more nuanced understanding of behavioural responses to incentives over time, particularly after they are removed, could guide more effective interventions. In this study, we build on the ...

Background Secondary prevention is critical for patients with established atherosclerotic cardiovascular diseases (ASCVD).